Skip to main content
Journal cover image

PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY

Publication ,  Conference
Ramsey, SD; Liu, Z; Boer, R; Malin, JL; Sullivan, SD; Doan, QV; Dubois, RW; Lyman, GH
Published in: Value in Health
May 2007

Duke Scholars

Published In

Value in Health

DOI

ISSN

1098-3015

Publication Date

May 2007

Volume

10

Issue

3

Start / End Page

A125 / A126

Publisher

Elsevier BV

Related Subject Headings

  • Health Policy & Services
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics
  • 1402 Applied Economics
  • 1117 Public Health and Health Services
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Ramsey, S. D., Liu, Z., Boer, R., Malin, J. L., Sullivan, S. D., Doan, Q. V., … Lyman, G. H. (2007). PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY. In Value in Health (Vol. 10, pp. A125–A126). Elsevier BV. https://doi.org/10.1016/s1098-3015(10)68920-6
Ramsey, S. D., Z. Liu, R. Boer, J. L. Malin, S. D. Sullivan, Q. V. Doan, R. W. Dubois, and G. H. Lyman. “PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY.” In Value in Health, 10:A125–26. Elsevier BV, 2007. https://doi.org/10.1016/s1098-3015(10)68920-6.
Ramsey, S. D., et al. “PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY.” Value in Health, vol. 10, no. 3, Elsevier BV, 2007, pp. A125–26. Crossref, doi:10.1016/s1098-3015(10)68920-6.
Ramsey SD, Liu Z, Boer R, Malin JL, Sullivan SD, Doan QV, Dubois RW, Lyman GH. PCN9 PRIMARY PROPHYLAXIS OF FEBRILE NEUTROPENIA WITH PEGFILGRASTIM IS COST-EFFECTIVE COMPARED WITH SECONDARY PROPHYLAXIS FOR WOMEN WITH EARLYSTAGE BREAST CANCER RECEIVING CHEMOTHERAPY. Value in Health. Elsevier BV; 2007. p. A125–A126.
Journal cover image

Published In

Value in Health

DOI

ISSN

1098-3015

Publication Date

May 2007

Volume

10

Issue

3

Start / End Page

A125 / A126

Publisher

Elsevier BV

Related Subject Headings

  • Health Policy & Services
  • 4407 Policy and administration
  • 4203 Health services and systems
  • 3801 Applied economics
  • 1402 Applied Economics
  • 1117 Public Health and Health Services